Sweden's CellaVision Q2 EBITDA falls on CEO transition costs
Sweden's CellaVision Q2 EBITDA falls on CEO transition costs
Overview
Sweden medical technology firm's Q2 net sales rose 4.5% yr/yr, organic sales up 5.6%
Q2 EBITDA margin fell to 27% from 31% due to CEO transition costs
Adjusted EPS declined to SEK 1.37 from SEK 1.58 yr/yr
Result Drivers
CEO TRANSITION COSTS - Co said Q2 EBITDA and margin were reduced by SEK 9 mln in expenses related to CEO transition
Company press release: ID:nMFN93ZdR2
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales |
| SEK 200 mln |
|
Q2 Adjusted EPS |
| SEK 1.37 |
|
Q2 EBITDA |
| SEK 55 mln |
|
Q2 EBITDA Margin |
| 27.00% |
|
Q2 Pretax Profit |
| SEK 41 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for CellaVision AB is SEK180.00, about 31.8% above its July 16 closing price of SEK136.60
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)